Pacira Biosciences (PCRX) Stock News

Pacira (Nasdaq: PCRX) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a live conference call and webcast at 4:30 p.m. ET following the release.

Investors who wish to ask questions by phone must pre-register to receive dial-in details and a PIN. A live audio webcast will be available on the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible on the Pacira website for about two weeks after the call.

Pacira BioSciences (NASDAQ: PCRX) reported updated three-year results from its open-label Phase 1 trial of PCRX-201 for moderate-to-severe osteoarthritis of the knee. A single ultrasound-guided intra-articular injection at each of three dose levels was well tolerated and produced sustained, clinically meaningful reductions in pain and stiffness and improvements in function through 156 weeks in 72 patients across two cohorts.

Key findings include no serious treatment-related adverse events, lower treatment-related index joint effusion rates with corticosteroid pretreatment (42% vs 67%), pre-existing anti-AD5 neutralizing antibodies did not affect outcomes, and results support a Phase 2 ASCEND strategy using a 10-fold lower dose (1.4E11 GC) with corticosteroid pretreatment. Findings were presented at ACR Convergence 2025.

Pacira (Nasdaq: PCRX) said it received a Paragraph IV Certification Notice from Qilu Pharmaceutical (Hainan) Co., Ltd., which filed an ANDA with the FDA seeking approval of a generic version of EXPAR EL. Qilu alleges invalidity or noninfringement of 18 Orange Book-listed patents (U.S. Patent Nos. 11,033,495 through 12,370,142).

Pacira says the contested patents belong to two families expiring on January 22, 2041 and July 2, 2044. Pacira intends to enforce its IP and has 45 days to sue, which would trigger an automatic 30‑month FDA stay on Qilu’s ANDA approval under Hatch‑Waxman.

Pacira BioSciences (NASDAQ: PCRX) will present new real-world and health-economic data for EXPAREL at the AMCP Nexus 2025 Annual Meeting, Oct 27–30 in National Harbor, MD. Presentations on Oct 29 (12:00–1:00 p.m. ET) include results from the multicenter prospective IGOR registry and three posters evaluating EXPAREL's association with pain, opioid use, function, length of stay, healthcare utilization, and costs in total knee and outpatient shoulder arthroplasty settings.

Abstracts are available in the Journal of Managed Care + Specialty Pharmacy supplement.

Pacira BioSciences (Nasdaq: PCRX) said it received a Paragraph IV Certification Notice Letter from The WhiteOak Group, which filed an ANDA with the FDA claiming a generic version of EXPAREL.

WhiteOak disputes claims of 19 EXPAREL patents listed in the Orange Book and asserts they are invalid, unenforceable, or not infringed. Pacira identified two patent families with expiration dates of January 22, 2041 and July 2, 2044. Pacira has 45 days from receipt to sue; filing would trigger an automatic 30-month stay of FDA approval under Hatch-Waxman.

Pacira BioSciences (NASDAQ: PCRX) will present new 3-year clinical data for investigational PCRX-201 (enekinragene inzadenovec), a high-capacity adenovirus serotype 5 gene therapy for knee osteoarthritis, at ACR Convergence 2025 in Chicago.

The poster reports sustained improvements in pain and function from a Phase 1 trial and lists safety observations; a Phase 2 ASCEND study is currently underway. Presentation by Stanley Cohen, MD is scheduled for Tuesday, October 28, 10:30 a.m.–12:30 p.m. CT.

Pacira BioSciences (NASDAQ: PCRX) announced on October 3, 2025 that it granted inducement equity awards on October 2, 2025 to 15 new employees under its Amended and Restated 2014 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Six employees received stock options for an aggregate of 18,000 shares (10-year term; exercise price $24.58; four-year vesting with 25% at one year). Fifteen employees received restricted stock units totaling 32,600 shares (vest annually in four equal installments beginning Oct 1, 2026). Vesting is subject to continued employment and award agreements.

Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has granted inducement awards to nine new employees under its Amended and Restated 2014 Inducement Plan. The awards, approved by the People & Compensation Committee on September 3, 2025, include:

• Stock Options: Six employees received options to purchase 13,000 shares at $27.18 per share, with a 10-year term and four-year vesting schedule
• Restricted Stock Units (RSUs): Nine employees received 18,100 RSUs, vesting annually in four equal installments starting September 1, 2026

Pacira BioSciences (Nasdaq: PCRX) reported Q2 2025 financial results with total revenues of $181.1 million. Key product sales included EXPAREL at $142.9 million, ZILRETTA at $31.3 million, and iovera° at $5.6 million. The company reported a net loss of $4.8 million ($0.11 per share) and adjusted EBITDA of $54.3 million.

Notable developments include surpassing 50% enrollment in the Phase 2 ASCEND study for PCRX-201, securing a new $300 million revolving credit facility, and entering a strategic collaboration with Johnson & Johnson MedTech. The company also received a $28.3 million favorable court ruling payment and strengthened its patent portfolio. Pacira updated its 2025 guidance, narrowing total revenue to $730-750 million and increasing non-GAAP gross margin to 78-80%.